PI
BLPH

Pennant Investors’s Bellerophon Therapeutics, Inc. BLPH Stock Holding History

Pennant Investors’s Portfolio BLPH Stock Details BLPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-70,132
Closed -$769K – 24
2020
Q1 		$769K Buy
+70,132
New +$470K 0.28% 21

Other funds holding BLPH

PCM
Puissance Capital Management New York $17.3M AUM 149.36% 1-Year Est. Return
NMVA
New Mountain Vantage Advisers New York $4.33B AUM 35.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TI
Telemetry Investments New York $63.3M AUM 0.06% 1-Year Est. Return
DC
Davenport & Co Richmond, Virginia $20.4B AUM 18.11% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Pennant Investors's BLPH Position: Q2 2020 in Review

Pennant Investors sold out of Bellerophon Therapeutics, Inc. (BLPH) in Q2 2020, closing a stake of 70,132 shares — an estimated $769K sold.

Pennant Investors first reported a position in BLPH in Q1 2020 and held it in 1 quarter. The position peaked at $769K in Q1 2020. 37 funds tracked by Wall St. Rank hold BLPH as of Q2 2020.

  • Pennant Investors reported no remaining Bellerophon Therapeutics, Inc. position as of Q2 2020 after selling out during the quarter.
  • Pennant Investors sold 70,132 Bellerophon Therapeutics, Inc. shares in Q2 2020, an estimated $769K.
  • Pennant Investors first reported a position in Bellerophon Therapeutics, Inc. in Q1 2020 and held it in 1 quarter.
  • Pennant Investors's Bellerophon Therapeutics, Inc. position peaked at $769K in Q1 2020.
  • 37 funds tracked by Wall St. Rank held Bellerophon Therapeutics, Inc. as of Q2 2020.

Based on Pennant Investors's 13F filing for Q2 2020, filed 14 Aug 2020.